We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Osteoarthritis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2011 by International Stemcell Services Limited.
Recruitment status was:  Enrolling by invitation
ClinicalTrials.gov Identifier:
First Posted: June 29, 2010
Last Update Posted: June 9, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
International Stemcell Services Limited

Osteoarthritis is a leading cause of chronic disability in elderly and the risk of disability attributed to osteoarthritis is as great as or greater than due to any other medical condition in that age group. Several cross sectional studies have demonstrated an age related increase in the prevalence of osteoarthritis of knee(5). Results of survey are similar with most surgeons reporting 50+ years age group being commonest at initial presentation and that the incidence increases with advancing age. Interestingly some surgeons have noticed earlier occurrence of osteoarthritis in 40+ years age group and one has to be careful to screen for secondary causes in this younger age group patients.

While pain relief is the primary treatment goal of osteoarthritis medications, localized inflammation may also be relieved by using certain drugs. Managing osteoarthritis pain can involve medications, natural remedies, exercise, weight loss, joint protection, mobility aids, assisted devices and more.

Stem cell therapy, using cells extracted from the same patient or suitable alternative human sources, targets diseases which are either incurable or with no complete or effective treatment available in the traditional healthcare system. Since this therapy is based on the concept of regenerating damaged cells in the injured or disease-affected areas of the body, it is called regenerative medicine

Autologous stem cells provide an attractive option for osteoarthritis patients and their clinicians.

In our present study we want to evaluate the safety and efficacy of autologous bone marrow derived stem cells in treatment of Osteoarthritis for therapeutic chondrogenesis through delivery of stem cells into the knee joint space in ten Indian patients.

Condition Intervention Phase
Osteoarthritis Other: Autologous bone marrow stem cells Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use of Autologous Bone Marrow Stem Cell Transplantation for Therapeutic Chondrogenesis in Moderate to Severe Osteoarthritis - ABM & LAM ST-OA Study

Resource links provided by NLM:

Further study details as provided by International Stemcell Services Limited:

Primary Outcome Measures:
  • Pain as measured by the The Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score [ Time Frame: Baseline, 3 months, 6 months, 1 year ]
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Changes in the MRI knee with cartilage mapping and clinical improvement [ Time Frame: Baseline, 6 months, 1 year ]

Estimated Enrollment: 10
Study Start Date: January 2010
Estimated Study Completion Date: January 2012
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Autologous bone marrow stem cells Other: Autologous bone marrow stem cells
Stem cells isolated from the patient's own bone marrow.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Must be able to give voluntary written (patients may not be able to write) consent.
  2. Must be able to understand study information provided to him.
  3. Age 30 to 70, inclusive
  4. OA Kellgren and Lawrence classification 3 & 4
  5. No ligamentous laxity i.e. stable
  6. Ability to understand and willingness to sign consent form
  7. The participant is able to comply with and understand the required visit schedule and all required tests and procedures.

Exclusion Criteria:

  1. Serious pre-existing medical conditions like Diabetes Mellitus, Chronic Renal Failure, Rheumatoid Arthritis, Collagen vascular diseases and Autoimmune diseases
  2. Pregnant or lactating woman
  3. Inflammatory arthritis
  4. Oral steroid, methotrexate (immune suppressants)
  5. History of drug or alcohol abuse or chronic smoking
  6. Poor patient compliance
  7. Infectious disease test positive for HIV 1&2, HbsAg, HCV and VDRL.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01152125

St. Theresa's Hospital
Bengaluru, Karnataka, India, 560010
Sponsors and Collaborators
International Stemcell Services Limited
Principal Investigator: Rudraprasad, M.S St. Theresa's Hospital
Study Director: Alphy Zachson, M.B.B.S International Stemcell Services Limited
  More Information

Responsible Party: Dr. SGA Rao, Chairman, International Stemcell Services Ltd.
ClinicalTrials.gov Identifier: NCT01152125     History of Changes
Other Study ID Numbers: ISSL-AuBM-OA
First Submitted: June 25, 2010
First Posted: June 29, 2010
Last Update Posted: June 9, 2011
Last Verified: June 2011

Keywords provided by International Stemcell Services Limited:
stem cell implantation
bone marrow

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases